Pharmacoeconomic Aspects of Using New Generation Drugs Of PCSK-9 Inhibitor and Acting on The Effect of Ribonucleic Acid Interference Classes in The Treatment of Patients With Hypercholesterolemia at High Risk of Cardiovascular Events

A. D. Ermolaeva; T. N. Ermolaeva; K. A. Kokushkin

For citations:

Ermolaeva A.D., Ermolaeva T.N., Kokushkin K.A. Pharmacoeconomic Aspects of Using New Generation Drugs Of PCSK-9 Inhibitor and Acting on The Effect of Ribonucleic Acid Interference Classes in The Treatment of Patients With Hypercholesterolemia at High Risk of Cardiovascular Events. Kardiologiia. 2025;65(6):23-33. https://doi.org/10.18087/cardio.2025.6.n2949

Views PDF (Rus): 180
Views PDF (Eng): 10

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Kardiologiia

For citations:

Cookies policy